Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease

Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397

C ERULOPLASMIN M ETABOLISM AND F UNCTION

Hellman, N. E., & Gitlin, J. D. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.012502.114457 · Cited by 954

Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease

Duce, J. A., Tsatsanis, A., Cater, M. A., James, S., Robb, E. L., Wikhe, K., Leong, S. L., Perez, K. A., Johanssen, T., Greenough, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.08.014 · Cited by 695

The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum.

Osaki, S., Johnson, D. A., & Frieden, E. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96527-0 · Cited by 679

Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo

Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export

Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594

The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity

Golts, N., Petrucelli, L., Hardy, J., Lee, J. M., Farer, M., & Wolozin, B. L. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06048.2000 · Cited by 550

Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury

Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J.-P., & David, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06578.2002 · Cited by 379

Individual dopaminergic neurons show raised iron levels in Parkinson disease

Oakley, A. E., Collingwood, J. F., Dobson, J., Love, G., Perrott, H. R., Edwardson, J. A., Elstner, M., & Morris, C. M. (2007) · Neurology · doi:10.1212/01.wnl.0000262033.01945.9a · Cited by 273

Sequestration of iron by Lewy bodies in Parkinson's disease

Castellani, R. J., Siedlak, S. L., Perry, G., & Smith, M. A. (2000) · Acta Neuropathologica · doi:10.1007/s004010050001 · Cited by 265

Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson’s disease

Zhao, N., Xiao, J., Zheng, Z.-Y., Fei, G., Zhang, F., Jin, L., & Zhong, C. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1512-6 · Cited by 8

Copper Mitigates Atrazine-Induced Neurotoxicity in Parkinson’s Disease Models

Li, B., Yang, R., Chen, X., He, J., Lu, Z., & Li, Y. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04609-3 · Cited by 7

Application and progress of transcranial substantial ultrasound in Parkinson's disease

Ma, X., Li, T., Du, L., & Han, T. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1091895 · Cited by 7

Metallomic analysis of brain tissues distinguishes between cases of dementia with Lewy bodies, Alzheimer’s disease, and Parkinson’s disease dementia

Scholefield, M., Church, S. J., Xu, J., & Cooper, G. J. S. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1412356 · Cited by 7

Ferroptosis and its modulators: A raising target for cancer and Alzheimer’s disease

Singh, G., Kesharwani, P., Singh, G. K., Kumar, S., Putta, A., & Modi, G. P. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117564 · Cited by 7

Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease

Song, Y. S., Kim, J., Kim, K. J., Yun, J. Y., & Kim, S. E. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001734 · Cited by 7

Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development

Fabbri, M., Perez‐Lloret, S., & Rascol, O. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1814252 · Cited by 7

Ferroptosis in Parkinson’s disease: a review of molecular mechanisms and emerging therapeutic strategies

Wang, L., Zhang, Y., & Guo, L. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1780573 · Cited by 7

Neurotoxicity of copper and copper nanoparticles

Joshi, A., Farber, K., & Scheiber, I. F. (2021) · Advances in neurotoxicology · doi:10.1016/bs.ant.2020.11.001 · Cited by 6

Fundamental Neurochemistry Review: Copper availability as a potential therapeutic target in progressive supranuclear palsy: Insight from other neurodegenerative diseases

Billings, J. L., Hilton, J. B. W., Liddell, J. R., Hare, D. J., & Crouch, P. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15978 · Cited by 7

Dyshomeostasis of Iron and Its Transporter Proteins in Cypermethrin-Induced Parkinson’s Disease

Sachan, N., Tiwari, N., Patel, D. K., Katiyar, D., Srikrishna, S., & Singh, M. P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03436-2 · Cited by 6

Oxidized/deamidated-ceruloplasmin dysregulates choroid plexus epithelial cells functionality and barrier properties via RGD-recognizing integrin binding

Zanardi, A., Barbariga, M., Conti, A., Vegliani, F., Curnis, F., & Alessio, M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105474 · Cited by 6

Emerging roles and therapeutic potentials of ferroptosis: from the perspective of 11 human body organ systems

Tan, Y., Dong, X., Zhuang, D., Cao, B., Jiang, H., He, Q., & Zhao, M. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04694-3 · Cited by 5

Meta-analysis of transcriptomic changes in optic nerve injury and neurodegenerative models reveals a fundamental response to injury throughout the central nervous system.

Donahue, R., Trane, R. M., & Nickells, R. W. (2017) · PubMed Central · Cited by 5

Thiol-Disulfide Homeostasis, Serum Ferroxidase Activity, and Serum Ischemia Modified Albumin Levels in Childhood Iron Deficiency Anemia

Topal, İ., Mertoğlu, C., Kara, İ. S., Gök, G., & Erel, Ö. (2019) · Fetal and Pediatric Pathology · doi:10.1080/15513815.2019.1627626 · Cited by 5

Ferroptosis in Nervous System Diseases

Wan, J., Yang, X., & Wang, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-26780-3_10 · Cited by 5

AMPK mediates the anti-ferroptosis effect of acupuncture in cerebral ischemia–reperfusion rats

Wang, R., & Xu, J. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149662 · Cited by 5

Identification of Potential Ferroptosis Key Genes in the Pathogenesis of Lumbosacral Spinal Root Avulsion by RNA Sequencing and Bioinformatics Analysis

Zhou, Z., Lu, J., Ma, J., & Zhu, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.902607 · Cited by 4

Integrated elemental analysis supports targeting copper perturbations as a therapeutic strategy in multiple sclerosis

Hilton, J. B. W., Kysenius, K., Liddell, J. R., Mercer, S. W., Rautengarten, C., Hare, D. J., Buncic, G., Paul, B. T., Murray, S. S., McLean, C., et al. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00432 · Cited by 4

Alterations in iron levels in the locus coeruleus of a transgenic Alzheimer’s disease rat model

Bhagaloo, K. A., Yu, L., West, E. A., Chandler, D. J., & Shcherbik, N. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138151 · Cited by 3

Oxidation of Iron under Physiologically Relevant Conditions in Biological Fluids from Healthy and Alzheimer’s Disease Subjects

Lam, L. Q., Wong, B. X. W., Frugier, T., Li, Q., Collins, S. J., Bush, A. I., Crack, P. J., & Duce, J. A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00411 · Cited by 3

Nouvelle stratégie de neuroprotection basée sur la chélation conservatrice du fer dans la maladie de Parkinson

Moreau, C., Rolland, A., Guyon, P., Devedjian, J.-C., Deplanque, D., Bordet, R., Carrière, N., Defebvre, L., & Devos, D. (2019) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2019.04.019 · Cited by 3

Metal Transporters in Neurodegeneration

Jiang, H. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00016-6 · Cited by 3

Preventing Neurons and Glial Cells Destruction in Substantia Nigra Pars Compacta and Striatum Using St. John's Wort and Stem Cells on Parkinson's Model

Farzadmanesh, H., Sameni, H., Ghanbari, A., Vafaei, A. A., Khaleghian, A., Mirmohammadkhani, M., Ghahari, L., Shokri, A., & Safari, M. (2025) · Brain and Behavior · doi:10.1002/brb3.71124 · Cited by 2

Metals and Mitochondria in Neurodegeneration

Plascencia‐Villa, G., José–Yacamán, M., & Perry, G. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00015-4 · Cited by 2

Eisen im alternden Gehirn

Küpper, C., Levin, J., & Klopstock, T. (2017) · Neuroradiologie Scan · doi:10.1055/s-0043-103529 · Cited by 2

Mutual relationship between serum ferroxidase activity and hemoglobin levels in elderly individuals

Romani, A., Trentini, A., Passaro, A., Bosi, C., Bellini, T., Ferrari, C., Cervellati, C., & Zuliani, G. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2709-8 · Cited by 2

Iron reduces the propagation of pathological α‐synuclein

Guo, Y., Ayton, S., & Lei, P. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15467 · Cited by 2

Automated ladder rung test for evaluating motor coordination in Parkinson’s disease mouse models

Zhang, P., Xu, W., Jiang, W., Jin, X., Lou, Y., Yang, T., Li, W., Gao, K., Gao, F., & Qian, Z. (2025) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2025.110642 · Cited by 1

Cellular and Molecular Mechanisms Contributing to Parkinson’s Disease

Madhuranthagan, M., Benito Johnson., D., Essly Selva Jasmine., P., Suresh., R., & Senthil Kumar., C. (2026) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2026.00005 · Cited by 1

Decreased metallothionein-3 expression in the human spinal cord is a common feature of amyotrophic lateral sclerosis and multiple sclerosis

Gunn, A. P., Hilton, J. B. W., Mukherjee, S., Liddell, J. R., Mercer, S. W., McLean, C. A., Masters, C. L., Crouch, P. J., & Roberts, B. R. (2026) · Scientific Reports · doi:10.1038/s41598-025-31283-9 · Cited by 1

Ceruloplasmin and neurodegeneration: A link between copper dysregulation, iron imbalance, and neuronal damage

Deepika, D., Kumar, J., Ali, S. A., Namdeo, A. G., & Flora, S. J. S. (2026) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2026.127929 · Cited by 1

Characterising the brain metalloproteome in Down syndrome patients with concomitant Alzheimer's pathology

Malakooti, N., Roberts, B. R., Pritchard, M. A., Volitakis, I., Kim, R. C., Lott, I. T., McLean, C., Finkelstein, D. I., & Adlard, P. A. (2019) · Metallomics · doi:10.1039/c9mt00196d · Cited by 1

Dual-action peptide shuttles prevent Cu-amyloid-β-induced neurotoxicity and relocate Cu intracellularly

Okafor, M., Schmitt, D., Falcone, E., Gasman, S., Raibaut, L., Hureau, C., Faller, P., & Vitale, N. (2026) · Inorganic Chemistry Frontiers · doi:10.1039/d6qi00862c · Cited by 1

The Ceruloplasmin Transferrin Ratio in the Blood of Patients at Different Stages of Parkinson’s Disease

Makletsova, M. G., Rikhireva, G. T., Poleschuk, V. V., & Illarioshkin, S. N. (2017) · BIOPHYSICS · doi:10.1134/s0006350917060148 · Cited by 1

Editorial for “Serum Ceruloplasmin Depletion is Associated With the Widespread Accumulation of Brain Iron in Parkinson's Disease”

Gupta, R. K. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27694 · Cited by 1

Pathometallomics: Taking Neurodegenerative Disease as an Example

Du, X., Li, X., & Liu, Q. (2024) · Wiley eBooks · doi:10.1002/9783527840397.ch10 · Cited by 1

Astrocytic Ceruloplasmin Deficiency Triggers Iron Toxicity and Neurodegeneration in a LRRK2 Parkinson's Tri-Culture ModelPreprint

Testa, V., Montero-Muñoz, J., Baruffi, V., Alzeer, M., Mularoni, L., Fernández‐Carasa, I., Simmini, G., Comellas-Comaposada, N., Ake, F. A., Richaud, Y., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.08.01.668099 · Cited by 1

Measuring brain iron in healthy controls and assessing venous abnormalities in Parkinson's disease using MRI

Liu, M. (2014)

News from the International Congress of Parkinson's Disease and Movement Disorders

Talan, J. (2016) · Neurology Today · doi:10.1097/01.nt.0000490354.26741.b3

Quantitative assessment of brain iron content as a function of age using magnetic resonance imaging

Ghassaban, K. (2016) · Human Biology

Nouvelle stratégie de neuroprotection basée sur la chélation conservatrice du fer dans la maladie de Parkinson

Rolland, A., Moreau, C., Devedjian, J.-C., Deplanque, D., Bordet, R., Carrière, N., Defebvre, L., & Devos, D. (2019) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2019.01.008

Copper and the Brain

Naheed, D., & Khurana, D. (2016) · Journal of Postgraduate Medicine Education and Research · doi:10.5005/jpmer-50-1-v

Copper and zinc level alterations in the brain structures in Parkinson’s and Alzheimer’s diseases

Николаевич, С. В., & Худоерков, Р. М. (2020) · CLINICAL AND EXPERIMENTAL MORPHOLOGY · doi:10.31088/cem2020.9.3.21-26

Ferroptosis a Futuristic Roadmap for Cancer and Alzheimer's DiseasePreprint

Singh, G., Kesharwani, P., Kumar, B., Mishra, I., Kumar, S., & Modi, G. P. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4091174

The Critical Roleplay of Iron Neurochemistry in Progression of Parkinson’s Disease

Sharma, G., Kadian, M., Sharma, K., Pandita, S., Shrivasatava, K., & Kumar, A. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-7327-7_5

Dyshomeostasis of iron and its transporter proteins in cypermethrin-inducedParkinson’s diseasePreprint

Sachan, N., Tiwari, N., Patel, D. K., Katiyar, D., Srikrishna, S., & Singh, M. P. (2022) · Research Square · doi:10.21203/rs.3.rs-2375066/v1

The Roles of Iron and Ferroptosis in Human Chronic Diseases

Shi, Y., Zhang, J., Luo, K., Pan, S., Shi, H., Xiong, L., & Du, S. (2023) · Biochemistry · doi:10.5772/intechopen.108790

Ferroptosis Modulators: A Potential Therapeutic Target in Alzheimer’s Disease

Singh, G., Rana, N. K., Mishra, I., & Modi, G. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-6038-5_14

THE RELATIONSHIP BETWEEN OXIDATIVE STRESS AND NEUROLOGICAL DISORDERS: MINI REVIEW

Kulbayeva, Z., Klyuyev, D. A., Sh, S. K. (., & Muratbek, A. A. (2024) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2024.36.46.010

Perturbations in levels of essential metals less severe in Parkinson’s disease without dementia than in Parkinson’s disease dementia

Scholefield, M., Church, S. J., & Cooper, G. J. S. (2025) · Metallomics · doi:10.1093/mtomcs/mfaf006

WITHDRAWN: AMPK mediates the anti-ferroptosis effect of acupuncture in cerebral ischemia-reperfusion ratsPreprint

Wang, R., & Xu, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.19.639025

Mechanism of cuproptosis in pathogenesis of Parkinson’s disease

Vashchenko, V. I., Chukhlovin, A. B., & Shabanov, P. D. (2025) · Психофармакология и биологическая наркология · doi:10.17816/phbn678545

Epigenetic effects of AtreMorine in Parkinson’s disease

Naidoo, V., Martínez-Iglesias, O. A., & Cacabelos, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00009-8

Disease Modeling and Drug Development Using Patient-Derived and Genome-Edited Pluripotent Stem Cells

Hayashi, Y. (2025) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-94101-6_1

Comparative effects of different molecular forms of eicosapentaenoic acid in ameliorating 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease via inhibition of ferroptosis in C57BL/6 mice

Wu, J., Wang, C., Wang, Y., Xue, C., Wang, Y., Zhang, L., Abdelnaby, T., El-Waseif, M., & Zhang, T. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.108174

The Synergistic Potential of Copper Nanoparticles and Saccharum Officinarum Phytochemicals in the Modulation of Neurodegeneration in Parkinson’s Disease: Insights from Siddha Inspired Approach

Shanmugam., M., Balamani, S., & Nihar, S. S. (2026) · International Journal of Research and Review · doi:10.52403/ijrr.20260110

Characterising the role of alpha synuclein in Ferroptosis, in the context of Parkinson's Disease

Mahoney‐Sanchez, L. (2022) · theses.fr (ABES) · doi:10.70675/a7f080d0z9ffaz4e1ez9550z0e29c4958e66

Rôle du métabolisme des acides gras polyinsaturés et du fer dans la vulnérabilité des neurones dopaminergiques à la ferroptose : nouvelles approches pharmacologiques pour la maladie de Parkinson.

Bouchaoui, H. (2024) · theses.fr (ABES) · doi:10.70675/e68098e9z03c2z494bza798zfc26b3eb872c

Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases

Liu, X., Jia, L., Wu, K., Chen, M., Sun, J., Yang, C., Xu, C., Sun, J., Wang, J., & Dai, L. (2026) · MedComm · doi:10.1002/mco2.70766

Troxerutin mitigates ferroptosis-related neuroinflammation by regulating the microglial NOX4/Nrf2 axis in Parkinson's disease

Wang, Q., Xu, X., Liu, Z., Wang, R., Lan, X., Li, J., Wang, S., (1668358), Z. S., Shi, L., Gao, Y., et al. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.06.006

Chronic α-Synuclein Over-Expression and Ceruloplasmin Challenge Promote Distinct Iron and Redox Responses in M17 CellsPreprint

Pourhadi, M., Ranxhi, B., Sukaria, S. P., Hussein, F. H., Todi, S. V., LeWitt, P. A., & Tsou, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.15.732494

Astrocytes in Parkinson’s disease: Beyond support, toward therapy

Wu, S., Wang, W., Yang, L., Pan, S., Thomas, E. R., & Li, X. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115964

BindingDB Entry 50021757: Ferroptosis and its modulators: A raising target for cancer and Alzheimer's disease.

BindingDB (2025) · UC San Diego · doi:10.7270/q21z492q

Functional relevance of ceruloplasmin mutations in Parkinson's Disease

Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

Grolez, G., Moreau, C., Sablonnière, B., Garçon, G., Devedjian, J.-C., Meguig, S., Gelé, P., Delmaire, C., Bordet, R., Defebvre, L., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0331-3 · Cited by 101

Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury

Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J.-P., & David, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06578.2002 · Cited by 379

Ceruloplasmin functional changes in Parkinson’s disease-cerebrospinal fluid

Barbariga, M., Curnis, F., Andolfo, A., Zanardi, A., Lazzaro, M., Conti, A., Magnani, G., Volonté, M. A., Ferrari, L. D., Comı, G., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0055-2 · Cited by 47

Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention

Olivieri, S., Conti, A., Iannaccone, S., Cannistraci, C. V., Campanella, A., Barbariga, M., Codazzi, F., Pelizzoni, I., Magnani, G., Pesca, M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3768-11.2011 · Cited by 125